COPD Clinical Trials in New York

Showing 21-40 of 116 trials

Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD

NCT02341326

Early changes associated with the development of smoking-induced diseases, e.g., COPD and lung cancer (the two commonest causes of death in U.S.) are often characterized by abnormal airway epithelial differentiation. Airway basal cells (BC) are stem/progenitor cells necessary for generation of differentiated airway epithelium. Based on our preliminary observations on SAE BC cells and FGFR2 signaling, we hypothesized that suppression of FGFR2 signaling in the SAE BC stem/progenitor cells by cigarette smoking renders these cells less potent in generating and maintaining normally differentiated SAE, shifting these cells towards a COPD associated phenotype. To test this, SAE basal cells will be isolated from cultured cells obtained through bronchoscopic brushings and analyzed through in vitro assays for their stem/progenitor capacities.

COPDSmokingLung Disorder

Weill Medical College of Cornell University111 participantsStarted Jul 2014

New York, New York, United States

COMPLETED< 1 mile

Observational Study of Obstructive Lung Disease (NOVELTY)

NCT02760329

The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis, or suspected diagnosis, of asthma and/or Chronic Obstructive Pulmonary Disease (COPD). Patients will undergo clinical assessments and receive standard medical care as determined by their treating physician. Patients enrolled in NOVELTY will be followed up yearly by their treating physician for a total duration of three years. In addition, patients will be followed up remotely every 3 months. The NOVELTY study will collect data currently lacking to allow for multinational data collection to fill regional/local gaps and improve comparability across regions.

AsthmaCOPDChronic Obstructive Pulmonary Disease

AstraZeneca12,255 participantsStarted Jul 2016

Loma Linda, California, United States • Long Beach, California, United States • Roseville, California, United States +328 more locations

Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD

Observational Study of Obstructive Lung Disease (NOVELTY)

COPD Trials in Other Cities

Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Improving Quality by Maintaining Accurate Problems in the EHR

A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD

Impairments That Affect Correct Inhaler Use in COPD

Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation

Communication During Hospitalization About Resuscitation Trial

Music During Pulmonary Rehabilitation for Patients With COPD

Bioequivalence Study of Tiotropium Bromide Inhalation Powder

Exacerbations and Their Outcomes International (EXACOS International)

Evaluation of VQm PHM on Pulmonary Health Parameters for ICU

Other Conditions in New York